LEDGF/p75 Integrase Inhibitors for HIV Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiretroviral therapies targeting HIV-1 reverse transcriptase and protease face limitations due to toxicity and the development of resistant strains, necessitating new agents that inhibit HIV replication, particularly those targeting alternative sites like the interaction between Lens Epithelial Derived Growth Factor (LEDGF/p75) and HIV-1 integrase.
Innovation Solution
Development of specific compounds, including their pharmaceutically acceptable salts, designed to target and inhibit the interaction between LEDGF/p75 and HIV-1 integrase, potentially offering a new approach to treating HIV by delaying the onset of AIDS or ARC symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If drugs targeting reverse transcriptase and protease are used, then HIV replication is inhibited, but toxicity and development of resistant strains occur
Solution Approach 1:
The patent extracts the therapeutic effect from the conventional drug targets (reverse transcriptase and protease) and relocates it to a new target: the interaction interface between LEDGF/p75 and HIV-1 integrase. By designing compounds that specifically bind to this protein-protein interaction interface, the invention achieves HIV replication inhibition through a completely different mechanism, thereby avoiding the toxicity and resistance problems associated with existing antiretroviral drugs.
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that bind to the LEDGF/p75-integrase interaction interface. These compounds act as mediators that disrupt the natural interaction between LEDGF/p75 and HIV-1 integrase, preventing viral integration without affecting the function of reverse transcriptase or protease. This intermediary approach allows selective inhibition of viral replication while sparing the host cell from toxic effects.
2Adaptability or versatility
If new agents targeting LEDGF/p75 and HIV-1 integrase interaction are developed, then alternative site inhibition is achieved, but compound structure complexity increases
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups positioned to interact with particular residues in the LEDGF/p75-integrase interface. The molecular structure incorporates specific pharmacophoric elements (such as hydrogen bond donors/acceptors, hydrophobic regions, and electrostatic interaction sites) at precise locations to optimize binding affinity and selectivity for this protein-protein interaction interface, thereby achieving effective inhibition without excessive structural complexity.
Data Source
AI summary
The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).